Jan 5, 2009
Genmab Announces Interim Results in Pivotal Study of Zalutumumab in Head and Neck Cancer

Dec 18, 2008
Genmab Sells Arzerra Co-Promotion Rights to GlaxoSmithKline

Dec 17, 2008
Grant of Warrants in Genmab A/S

Dec 10, 2008
Genmab’s Financial Calendar for 2009

Dec 8, 2008
Arzerra™ (Ofatumumab) Demonstrates High Response Rates in Patients with Fludarabine Refractory Chronic Lymphocytic Leukaemia (CLL)

Nov 28, 2008
Genmab’s Total Number of Voting Rights and Total Share Capital

Nov 10, 2008
Ofatumumab Pivotal CLL Data to be Presented at ASH